Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 7/20 | 0.35 |
| ▸ | KLK7 | P49862 | 2/20 | 0.35 |
| ▸ | CTSK | P43235 | 4/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.34 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 2/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | BCL2 | P10415 | 1/20 | 0.34 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30788941 | 1.00 | SLC6A9 (0.35) | SLC6A9KLK7CTSKCYP3A4SCN9A | |
| SCHEMBL32670628 | 1.00 | SLC6A9 (0.35) | SLC6A9KLK7CTSKCYP3A4SCN9A | |
| SCHEMBL30788826 | 0.93 | PPARA (0.39) | SLC6A9CTSKCYP3A4SCN9APPARA | |
| SCHEMBL30788874 | 0.92 | BCHE (0.39) | SLC6A9CTSK | |
| SCHEMBL30788889 | 0.91 | SLC6A9 (0.36) | SLC6A9KLK7CTSKCYP3A4SCN9A | |
| SCHEMBL32670437 | 0.83 | KLK7 (0.40) | KLK7CTSKCYP3A4SCN9AP2RY2 | |
| SCHEMBL30788759 | 0.80 | CTSK (0.40) | CTSKCYP3A4SCN9ACACNA1BPPARG | |
| SCHEMBL32670597 | 0.78 | CTSK (0.34) | CTSKCACNA1BP2RY2MMP13 | |
| SCHEMBL32670695 | 0.77 | CTSK (0.37) | CTSKCACNA1BP2RY2 | |
| SCHEMBL30788862 | 0.76 | PPARA (0.43) | KLK7CTSKCYP3A4SCN9APPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034094-A1 | COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS | KOJIN THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034094-A1 | COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS | AIFM2, GPX4, HMOX1 | SLC6A9 1336/4885KLK7 4752/4885CTSK 1113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.